PRTG - Portage Biotech Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.6600
+0.1800 (+5.17%)
At close: 03:59PM EDT
3.7400 +0.08 (+2.19%)
After hours: 04:41PM EDT
Stock chart is not supported by your current browser
Previous Close3.4800
Open3.4800
Bid3.6600 x 2200
Ask3.7400 x 800
Day's Range3.4800 - 3.7500
52 Week Range2.3400 - 11.9900
Volume28,915
Avg. Volume23,320
Market Cap63.697M
Beta (5Y Monthly)108.70
PE Ratio (TTM)N/A
EPS (TTM)-1.2800
Earnings DateJul 31, 2023 - Aug 04, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.33
  • GlobeNewswire

    Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

    Ian Walters, M.D. to serve as expert panelist discussing the future of immune checkpoint inhibitorsWESTPORT, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that CEO Dr. Ian Walters will serve as an expert spokesperson on an oncology panel discussion at the upcoming BIO International Conference taking place in Boston, Massach

  • GlobeNewswire

    Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

    WESTPORT, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced the acceptance of a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. The poster will include updated data from the Company’s Phase 1/2 trial evaluating its lead invariant natural killer T cel

  • GlobeNewswire

    Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference

    WESTPORT, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will be presenting virtually at Oppenheimer’s 33rd Annual Healthcare Conference on March 13-15, 2023. Presentation details are below: Oppenheimer 33rd Annual Healthcare Conference Date / Time:Tuesday, March 14, 2023 at 2:00 – 2:30pm

  • GlobeNewswire

    Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

    - Enrollment ongoing in IMPORT-201 Phase 1/2 trial of PORT-2 in Melanoma and Non-Small Cell Lung Cancer - Company on track to initiate Phase 1 portion of ADPORT-601 trial by end of 2Q23 - Company to Host a Key Opinion Leader Event on Targeting Adenosine Pathway in Cancer WESTPORT, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announ

  • GlobeNewswire

    Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

    Targeting Adenosine for Cancer:Challenging Past Assumptions with Next-Generation Small Molecule Inhibitors Thursday, March 9th @ 10:30 am ET WESTPORT, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it will host a key opinion leader (KOL) webinar on targeting the adenosine pathway in cancer on Thursday, March 9, 2023 at

  • GlobeNewswire

    Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

    WESTPORT, Conn., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a fireside chat at Citi's 2023 Virtual Oncology Leadership Summit taking place on Febrarury 21 – 23, 2023. Event details are below: Citi's 2023 Virtual Oncology Leadership Summit Date / Time:Wednesday, February 22,

  • GlobeNewswire

    Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

    --Updated Data on Phase 1/2 Trial Evaluating PORT-2 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting-- --Clinical Collaboration Agreement Entered into with Merck for Evaluation of PORT-2 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with first-line and refractory non-small cell lung cancer (NSCLC)-- --Focused Clinical Development Goals on Producing Nine Phase 1b/Phase 2 Data Readouts in Multiple Tumor Types Over the Next Two Years-- WESTP

  • GlobeNewswire

    Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

    Updated data support the proof of concept of using an iNKT agonist monotherapy (PORT-2) to induce immune response for patients with refractory NSCLC and melanomaWESTPORT, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced the presentation of updates from its ongoing Phase 1/2 study of PORT-2 (IMM60), an invariant natural killer T cell (iNKT) ago

  • GlobeNewswire

    Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

    Study will evaluate PORT-2 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with front-line as well as refractory non-small cell lung cancer (NSCLC)WESTPORT, Conn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that it has entered into a

  • GlobeNewswire

    Portage Biotech Provides Research and Development Update

    --The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms-- --Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Over the Next two Years-- WESTPORT, Conn., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today provided an update on its research and development programs for its ex

  • GlobeNewswire

    Portage Biotech to Present at Upcoming Investor Conferences

    WESTPORT, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that the Company’s management team will be presenting at the following upcoming investor conferences: H.C. Wainwright 24th Annual Global Investment ConferenceDate / Time:September 13, 2022 at 9:30am ETFormat:Company Presentation Cantor Fitzgerald’s Oncology, Hematology, & HemeOnc Conf

  • GlobeNewswire

    Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

    --Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced financial results for the fiscal

  • GlobeNewswire

    Portage Biotech Announces Leadership Updates

    CEO Dr. Ian Walters to take on additional responsibility as Chairman of the Board Justin Fairchild, MPH, an expert in clinical immunotherapy, appointed Vice President of Development WESTPORT, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that Dr. Ian Walters, Chief Executive Officer of Portage, will be appointed Chairman of Portage’s Board

  • GlobeNewswire

    UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

    --Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming

  • GlobeNewswire

    Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

    --Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming

  • GlobeNewswire

    Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

    Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company has acquired the outstanding ownership interest (approximately 22%) of its invariant natural kille

  • GlobeNewswire

    Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

    Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at OrbiMed, to join the Portage Board of Directors Enters into committed share purchase agreement with Lincoln Park Capital to purchase ordinary shares of Portage for up to $30 Million; proceeds to potentially extend cash runway for current projects into 2024 Management to host a conf

  • GlobeNewswire

    Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

    Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as a monotherapy with translational data supporting its mechanism of actionWESTPORT, Conn., June 06, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company presented early data from its Phase 1/2